Latest DHR news

Danaher Schedules Third Quarter 2026 Earnings Conference Call

PRNewsWire · Tue, 22 Sep 2026 16:15:00 -0400

WASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m.

Danaher Announces Quarterly Dividend

PRNewsWire · Tue, 15 Sep 2026 16:15:00 -0400

WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.

ELV or DHR: Which Is the Better Value Stock Right Now?

Zacks Investment Research · Tue, 15 Sep 2026 12:40:50 -0400

Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

Why Moderna's Cancer Vaccine Matters to Investors

ETF Trends · Wed, 02 Sep 2026 12:04:57 -0400

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?

Zacks Investment Research · Tue, 25 Aug 2026 11:06:12 -0400

DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

24/7 Wall Street · Tue, 25 Aug 2026 07:15:43 -0400

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.

Danaher: 2027 Growth Reacceleration Should Drive Upside

Seeking Alpha · Fri, 14 Aug 2026 15:26:06 -0400

Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR's valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding.

Market information is provided for research and visualization and is not investment advice.